Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
Jump to:
Id | http://purl.obolibrary.org/obo/NCIT_C77888
http://purl.obolibrary.org/obo/NCIT_C77888
|
---|---|
Preferred Name | Ruxolitinib |
Definitions |
An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.
|
Type | http://www.w3.org/2002/07/owl#Class |
All Properties
definition | An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies. |
---|---|
label |
Ruxolitinib
|
prefLabel |
Ruxolitinib
|
Legacy Concept Name |
Oral_JAK_Inhibitor_INCB18424
|
in_subset |
See more
See less
|
Preferred_Name |
Ruxolitinib
|
Is_Value_For_GDC_Property | |
Chemical_Formula |
C17H18N6
|
Display_Name |
Ruxolitinib
|
Maps_To |
Ruxolitinib
|
Has_Target | |
UMLS_CUI |
C2715577
|
FDA_UNII_Code |
82S8X8XX8H
|
prefixIRI |
NCIT:C77888
|
Accepted_Therapeutic_Use_For |
steroid-refractory acute graft-versus-host disease (GVHD)
|
Contributing_Source |
CTRP
FDA
|
subClassOf | |
Has_Salt_Form | |
code |
C77888
|
type | |
Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
CAS_Registry |
941678-49-5
|
Add comment
Delete | Subject | Author | Type | Created |
---|---|---|---|---|
No notes to display |